Diethyldithiocarbamate
A randomized placebo-controlled multicenter used diethyldithiocarbamate
for chemoprotection against CiO in patients with lung or ovarian cancer.
Patients who received diethyldithiocarbamate received lower cumulative
doses of cisplatin, were more likely to be withdrawn from treatment
early due to chemotherapy-related toxicities, and had a trend for a
greater reduction in auditory acuity at 3000 Hz (P = 0.095)(Gandara et
al., 1995).